MGMT promoter methylation and hypermutant recurrence in IDH mutant lower-grade glioma

被引：6
|
作者：
Miller, Julie J. [1 ,2 ]
Cahill, Daniel P. [1 ,3 ]
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Translat Neurooncol Lab, Boston, MA 02115 USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Div Neurooncol, Dept Neurol, Boston, MA 02115 USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02115 USA
来源：
NEURO-ONCOLOGY | 2020年 / 22卷 / 11期
关键词：
glioma; IDH1; mutation; temozolomide; TEMOZOLOMIDE; PROCARBAZINE; VINCRISTINE; PROGRESSION; LOMUSTINE; EVOLUTION; THERAPY; BENEFIT;
D O I：
10.1093/neuonc/noaa212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1553 / 1554
页数：2
相关论文
共 50 条
  • [1] MGMT promoter methylation and survival following chemotherapy for WHO grade 4 IDH-mutant astrocytoma
    Lim-Fat, Mary Jane
    Wen, Patrick Y.
    Touat, Mehdi
    Puduvalli, Vinay K.
    Iorgulescu, J. Bryan
    NEURO-ONCOLOGY, 2024, 26 (12) : 2388 - 2390
  • [2] THE PROGNOSTIC IMPLICATION OF MGMT PROMOTER METHYLATION IN IDH-MUTANT GLIOMAS
    Youssef, Gilbert
    Aquilanti, Elisa
    Muzikansky, Alona
    Miller, Julie
    Vogelzang, Jayne
    Lapinskas, Emily
    Lim-Fat, Mary Jane
    Rahman, Rifaquat
    Beroukhim, Rameen
    Bi, Wenya Linda
    Chukwueke, Ugonma
    Castro, Luis Nicolas Gonzalez
    Lee, Eudocia
    McFaline-Figueroa, J. Ricardo
    Nayak, Lakshmi
    Reardon, David A.
    Ligon, Keith
    Wen, Patrick Y.
    NEURO-ONCOLOGY, 2022, 24 : 153 - 153
  • [3] MGMT promoter methylation is present in low grade glioma (WHO Grade II/III) and glioblastoma multiforme in the absence of IDH mutations
    Haynes, H. R.
    Crosby, C.
    Williams, H.
    White, P.
    Hopkins, K.
    Williams, M.
    Kurian, K. M.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2014, 40 : 47 - 48
  • [4] MGMT PROMOTER METHYLATION IS PRESENT IN LOW GRADE GLIOMA (WHO GRADE II/III) AND GLIOBLASTOMA MULTIFORME IN THE ABSENCE OF IDH MUTATIONS
    Haynes, Harry R.
    Crosby, Charlene
    Williams, Hannah
    White, Paul
    Hopkins, Kirsten
    Williams, Maggie
    Kurian, Kathreena M.
    NEURO-ONCOLOGY, 2013, 15 : 142 - 142
  • [5] MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence
    Mathur, Radhika
    Zhang, Yalan
    Grimmer, Matthew R.
    Hong, Chibo
    Zhang, Michael
    Bollam, Saumya
    Petrecca, Kevin
    Clarke, Jennifer
    Berger, Mitchel S.
    Phillips, Joanna J.
    Oberheim-Bush, Nancy Ann
    Molinaro, Annette M.
    Chang, Susan M.
    Costello, Joseph F.
    NEURO-ONCOLOGY, 2020, 22 (11) : 1580 - 1590
  • [6] PROGNOSTIC IMPACT OF EXTENDED RESECTIONS IN IDH MUTANT LOWER-GRADE DIFFUSE GLIOMA: RESULTS FROM A VOLUMETRIC ANALYSIS
    Jungk, Christine
    Gluszak, Mara
    von Deimling, Andreas
    Herold-Mende, Christel
    Trong, Philip Dao
    Unterberg, Andreas
    NEURO-ONCOLOGY, 2023, 25
  • [7] The association between IDH1 mutation and MGMT promoter methylation in Indonesian glioma patients
    Hudiana, Dina
    Malueka, Rusdy
    Dananjoyo, Kusumo
    Asmedi, Ahmad
    Dwianingsih, Ery Kus
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [8] PROGNOSTIC VALUE OF MGMT METHYLATION IN IDH MUTANT GLIOMAS
    Lam, Keng
    Eldred, Blaine
    Kevan, Bryan
    Ji, Matthew
    Lou, Jerry
    Pianka, Sean
    Yong, William
    Liau, Linda
    Nghiemphu, Phioanh
    Cloughesy, Timothy
    Green, Richard
    Lai, Albert
    NEURO-ONCOLOGY, 2020, 22 : 8 - 8
  • [9] Deconvolution and network analysis of IDH-mutant lower grade glioma predict recurrence and indicate therapeutic targets
    Li, Guangqi
    Jiang, Yuanjun
    Lyu, Xintong
    Cai, Yiru
    Zhang, Miao
    Wang, Zuoyuan
    Li, Guang
    Qiao, Qiao
    EPIGENOMICS, 2019, 11 (11) : 1323 - 1333
  • [10] Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
    Chai, Ruichao
    Li, Guanzhang
    Liu, Yuqing
    Zhang, Kenan
    Zhao, Zheng
    Wu, Fan
    Chang, Yuzhou
    Pang, Bo
    Li, Jingjun
    Li, Yangfang
    Jiang, Tao
    Wang, Yongzhi
    CANCER BIOLOGY & MEDICINE, 2021, 18 (01) : 271 - +
12345